Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis

  • Technology appraisal guidance
  • TA386
  • Published: 

History

Documents created during the development process.

Expected publication

Final appraisal determination

Draft guidance

Equality impact assessment

Final scope

Final matrix

Draft scope

Provisional matrix